Novartis Investigative site

Odense DK 5000

0 studies enrolling now · 12 studies all time

What they study most

Allergy, Peanut, Chronic Obstructive Pulmonary Disease, Complicated Urinary Tract Infections, Fallopian Tube Cancer, Graft-versus-host Disease (GVHD), Melanoma, Multiple Myeloma, Neoplasms, Breast, Ovarian Cancer, Peritoneal Neoplasms, Psoriatic Arthritis, Purpura, Thrombocytopaenic, Idiopathic

Studies at this site

• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). — Completed
• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) — Completed
• Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy — Stopped early
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma — Completed
• Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer — Completed
• Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis — Completed
• Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma — Completed
• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis — Completed
• LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI) — Withdrawn before enrolling
• EXTEND (Eltrombopag Extended Dosing Study) — Completed
• The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease — Completed